Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Discovery | 3 | 2024 | 1057 | 0.620 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2024 | 5643 | 0.360 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2024 | 656 | 0.310 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2007 | 143 | 0.270 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1958 | 0.260 |
Why?
|
| Breast | 1 | 2014 | 1963 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 2873 | 0.230 |
Why?
|
| Mammography | 1 | 2014 | 2427 | 0.230 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 13630 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2023 | 5253 | 0.200 |
Why?
|
| Lead | 1 | 2007 | 880 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2020 | 183 | 0.170 |
Why?
|
| Epidermal Growth Factor | 1 | 2022 | 695 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 112 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 2 | 2022 | 944 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2023 | 362 | 0.160 |
Why?
|
| Proteomics | 2 | 2023 | 3817 | 0.160 |
Why?
|
| Small Molecule Libraries | 2 | 2024 | 734 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2019 | 1999 | 0.160 |
Why?
|
| Staining and Labeling | 1 | 2022 | 1089 | 0.150 |
Why?
|
| Cataloging | 1 | 2017 | 9 | 0.150 |
Why?
|
| Azepines | 1 | 2019 | 330 | 0.150 |
Why?
|
| Microscopy | 1 | 2022 | 885 | 0.150 |
Why?
|
| Ubiquitin | 1 | 2022 | 838 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2019 | 384 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2007 | 2560 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 346 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2019 | 556 | 0.130 |
Why?
|
| Cell Cycle | 2 | 2022 | 2934 | 0.120 |
Why?
|
| Thalidomide | 1 | 2019 | 884 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 1147 | 0.120 |
Why?
|
| Systems Biology | 1 | 2017 | 482 | 0.110 |
Why?
|
| Gamma Rays | 1 | 2014 | 317 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2024 | 10446 | 0.110 |
Why?
|
| Relative Biological Effectiveness | 1 | 2014 | 312 | 0.110 |
Why?
|
| Molecular Structure | 3 | 2024 | 1895 | 0.110 |
Why?
|
| Cell Survival | 1 | 2022 | 5797 | 0.100 |
Why?
|
| Pyrroles | 1 | 2019 | 1137 | 0.100 |
Why?
|
| Cell Line | 4 | 2023 | 15620 | 0.100 |
Why?
|
| Indoles | 1 | 2019 | 1829 | 0.100 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 16939 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 2418 | 0.090 |
Why?
|
| RNA | 1 | 2020 | 2722 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 2919 | 0.090 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 607 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2024 | 717 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 3446 | 0.080 |
Why?
|
| Neoplasms | 3 | 2022 | 22072 | 0.080 |
Why?
|
| Cadmium Radioisotopes | 1 | 2007 | 2 | 0.070 |
Why?
|
| Germanium | 1 | 2007 | 7 | 0.070 |
Why?
|
| Cyclotrons | 1 | 2007 | 30 | 0.070 |
Why?
|
| Structure-Activity Relationship | 2 | 2024 | 3084 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2023 | 4642 | 0.070 |
Why?
|
| Ovarian Neoplasms | 2 | 2021 | 4878 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8515 | 0.060 |
Why?
|
| Lead Poisoning | 1 | 2007 | 321 | 0.060 |
Why?
|
| Tumor Necrosis Factors | 1 | 2023 | 106 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2023 | 188 | 0.050 |
Why?
|
| Thiolester Hydrolases | 1 | 2022 | 85 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2023 | 250 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 20080 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5697 | 0.050 |
Why?
|
| Spheroids, Cellular | 1 | 2023 | 329 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 5799 | 0.040 |
Why?
|
| Caspases | 1 | 2023 | 878 | 0.040 |
Why?
|
| raf Kinases | 1 | 2019 | 118 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 454 | 0.040 |
Why?
|
| Humans | 17 | 2024 | 760621 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2022 | 772 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2007 | 2512 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 829 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2022 | 1008 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 736 | 0.040 |
Why?
|
| Phthalazines | 1 | 2019 | 383 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 642 | 0.030 |
Why?
|
| Organoids | 1 | 2023 | 729 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2021 | 704 | 0.030 |
Why?
|
| Computational Biology | 2 | 2019 | 3505 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2022 | 979 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 21025 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2019 | 559 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3276 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 1617 | 0.030 |
Why?
|
| Gene Library | 1 | 2017 | 1060 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2023 | 3157 | 0.030 |
Why?
|
| National Health Programs | 1 | 2017 | 441 | 0.030 |
Why?
|
| Apoptosis | 2 | 2021 | 9501 | 0.030 |
Why?
|
| Mice | 4 | 2024 | 81208 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 791 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1088 | 0.030 |
Why?
|
| Mammals | 1 | 2019 | 1131 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6131 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 2601 | 0.030 |
Why?
|
| Phenotype | 2 | 2022 | 16546 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 3607 | 0.030 |
Why?
|
| Cell Division | 1 | 2020 | 4463 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2017 | 822 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2007 | 4412 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 10827 | 0.020 |
Why?
|
| Animals | 5 | 2024 | 167963 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 1664 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14660 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3584 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1677 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2020 | 5434 | 0.020 |
Why?
|
| DNA Damage | 1 | 2019 | 2442 | 0.020 |
Why?
|
| Female | 7 | 2023 | 391270 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2020 | 8313 | 0.020 |
Why?
|
| Piperazines | 1 | 2019 | 2525 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5794 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3844 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4550 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14372 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9411 | 0.010 |
Why?
|
| United States | 2 | 2019 | 72461 | 0.010 |
Why?
|
| Male | 2 | 2020 | 359744 | 0.010 |
Why?
|
Concepts
(116)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(51)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_